Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial-Reference-Cited by-同舟云学术

Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial

Published:2022-10-20 Issue:1 Volume:12 Page:73-87
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Igarashi Hisaka,Shibata Mamoru,Ozeki Akichika^ORCID,Matsumura Taka

Funder

Eli Lilly Japan

Daiichi-Sankyo

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-022-00410-3.pdf

Reference35 articles.

1. Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022;163(2):e293–309.

2. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.

3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.

4. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.

5. Laurell K, Artto V, Bendtsen L, et al. Premonitory symptoms in migraine: a cross-sectional study in 2714 persons. Cephalalgia. 2016;36(10):951–9.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute and preventive treatment of menstrual migraine: a meta-analysis;The Journal of Headache and Pain;2024-09-04

2. Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment;Confinia Cephalalgica;2024-05-07

3. CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine;Medicina;2024-01-15

4. Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial;Neurology and Therapy;2023-09-12